TESARO Inc (TSRO) : Graticule Asia Macro Advisors added new position in TESARO Inc during the most recent quarter end. The investment management firm now holds 104,000 shares of TESARO Inc which is valued at $10,021,440 , the company said in a statement filed on Aug 15, 2016 with the SEC.TESARO Inc makes up approximately 4.11% of Graticule Asia Macro Advisors’s portfolio.
Other Hedge Funds, Including , Passport Capital added TSRO to its portfolio by purchasing 734,327 company shares during the most recent quarter which is valued at $70,759,750. TESARO Inc makes up approx 2.08% of Passport Capital’s portfolio. Senzar Asset Management added TSRO to its portfolio by purchasing 94,300 company shares during the most recent quarter which is valued at $9,086,748. TESARO Inc makes up approx 1.81% of Senzar Asset Management’s portfolio.Proshare Advisors boosted its stake in TSRO in the latest quarter, The investment management firm added 4,464 additional shares and now holds a total of 37,131 shares of TESARO Inc which is valued at $3,577,943. TESARO Inc makes up approx 0.04% of Proshare Advisors’s portfolio.Rhumbline Advisers boosted its stake in TSRO in the latest quarter, The investment management firm added 2,006 additional shares and now holds a total of 24,759 shares of TESARO Inc which is valued at $2,385,777. TESARO Inc makes up approx 0.01% of Rhumbline Advisers’s portfolio.Suffolk Capital Management reduced its stake in TSRO by selling 40,618 shares or 16.12% in the most recent quarter. The Hedge Fund company now holds 211,427 shares of TSRO which is valued at $19,747,282. TESARO Inc makes up approx 2.36% of Suffolk Capital Management’s portfolio.
TESARO Inc closed down -0.34 points or -0.40% at $84.35 with 4,63,213 shares getting traded on Thursday. Post opening the session at $85.14, the shares hit an intraday low of $83.26 and an intraday high of $85.5599 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, TESARO Inc reported $-1.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.42 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.70. The company had revenue of $36.60 million for the quarter, compared to analysts expectations of $2.48 million. During the same quarter in the previous year, the company posted $-1.51 EPS.
Many Wall Street Analysts have commented on TESARO Inc. Lake Street Resumed TESARO Inc on Sep 6, 2016 to “Buy”, Price Target of the shares are set at $114.BofA/Merrill Initiated TESARO Inc on Aug 30, 2016 to “Neutral”, Price Target of the shares are set at $97.RBC Capital Mkts Initiated TESARO Inc on Aug 12, 2016 to “Outperform”, Price Target of the shares are set at $122.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.